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Abstract—There is increasing interest in utilizing novel markers of cardiovascular disease risk, and consequently, there is
a need to assess the value of their use. This scientific statement reviews current concepts of risk evaluation and proposes
standards for the critical appraisal of risk assessment methods. An adequate evaluation of a novel risk marker requires
a sound research design, a representative at-risk population, and an adequate number of outcome events. Studies of a
novel marker should report the degree to which it adds to the prognostic information provided by standard risk markers.
No single statistical measure provides all the information needed to assess a novel marker, so measures of both
discrimination and accuracy should be reported. The clinical value of a marker should be assessed by its effect on patient
management and outcomes. In general, a novel risk marker should be evaluated in several phases, including initial proof
of concept, prospective validation in independent populations, documentation of incremental information when added
to standard risk markers, assessment of effects on patient management and outcomes, and ultimately, cost-effectiveness.
(Circulation. 2009;119:2408-2416.)
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Accurate assessment of cardiovascular risk is essential forclinical decision making, because the benefits, risks, and
costs of alternative management strategies must be weighed
to choose the best treatment for individual patients. Despite
its importance to optimal clinical and policy decisions, many
aspects of risk assessment are poorly understood. Critical
evaluation of risk markers and risk assessment methods has
become even more important as novel markers of cardiovas-
cular risk are identified by technological advances in genet-
ics, genomics, proteomics, and noninvasive imaging.1–3 The
purpose of this document is to provide a practical framework
for assessing the value of a novel risk marker and to propose
standards for the critical appraisal of risk assessment methods
that might be used clinically.
Evaluation of Risk
Risk assessment is applied to many different clinical out-
comes and in many distinct clinical domains. For instance,
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accurate prediction of procedural risk related to coronary
artery revascularization, carotid stenting, or pacemaker im-
plantation is important both to the patient deciding whether to
undergo the procedure and to those interested in quality
assessment of these procedures based on risk-adjusted out-
comes. Similarly, accurate risk assessment of the short-term
outcomes of acute illnesses such as acute myocardial infarc-
tion is important for both clinical care and quality improve-
ment. Risk assessment is also central to the use of preventive
therapies, such as prevention of embolic stroke in the setting
of atrial fibrillation, prevention of the development of coro-
nary artery disease in adults with cardiac risk factors, or the
prevention of sudden death in patients with cardiomyopathy.
Although the specific outcome of interest may be quite
different in various clinical domains, the same basic princi-
ples and methods apply to evaluation of risk markers and risk
assessment methods in each domain.
Assessment of cardiovascular risk in individuals is an
integral part of clinical decision making, especially for
increasing the rational use of pharmaceutical-, procedure-,
or device-based therapies. These individually targeted
interventions are complementary to public health activities
that aim to reduce the overall population risk of cardio-
vascular disease by the promotion of healthy behaviors
related to diet, exercise, and avoidance of smoking.
Evaluation of a new risk marker or risk assessment
method starts with a sound study design and a representa-
tive at-risk population. Cohort studies in which partici-
pants are followed up over time and outcomes are ascer-
tained prospectively provide the best information about
prognosis. The design and reporting of risk marker assess-
ment studies should conform to generally accepted stan-
dards of clinical research, such as the recent “Strengthening
the Reporting of Observational Studies in Epidemiology”
guidelines.4
The outcome measure must be defined carefully, measured
accurately, and ascertained completely to provide a reliable
basis for the evaluation of any risk marker or risk assessment
tool. The number of outcome events available for analysis can
be increased by use of a composite end point (eg, either death,
myocardial infarction, or ischemic stroke). Composite end
points may complicate the assessment of risk markers,
however, if the marker is more predictive of 1 component of
the composite end point (eg, myocardial infarction) than of
the others (eg, stroke, death). The number of events available
for analysis can also be increased by longer follow-up, but this
is appropriate only if the marker is associated with both
short-term and long-term risk. For instance, elevated biomarkers
of myocardial necrosis predict a higher short-term risk in acute
coronary syndrome but may not necessarily predict long-term
risk (ie, between 6 months and 5 years of follow-up).
Risk is estimated on the basis of the number of outcome
events over an interval of time and conventionally sum-
marized either with a survival curve or by reporting the
proportion of events over a fixed time interval of interest
(eg, 30 days or 1 year). The statistical association of a risk
marker with outcome can then be tested with logistic
regression (for a short, fixed follow-up interval) or with
the Cox proportional hazards model or a parametric
survival model (for a range of follow-up intervals or for
longer follow-up). These models generally assume that the
presence of a risk factor increases risk in a proportional
fashion, which can be assessed by measures of statistical
association such as the odds ratio, risk ratio, or hazard
ratio. Multivariable statistical models then measure the
extent to which underlying average risk in the population
is modified by standard demographic factors (eg, age, sex,
and race), established risk markers (eg, smoking, blood
pressure or lipid levels, diabetes), and the novel risk
marker. The use of these statistical models highlights
several very important issues about estimation of risk.
The most basic requirement for a novel risk marker is
that the association between the marker and the outcome of
interest be statistically significant when tested as a predic-
tor of future events. This test requires that the putative risk
marker has been measured in a cohort of subjects with a
sufficient number of documented outcome events to allow
a reliable analysis of risk relationships. Critically, the
statistical power of risk assessment depends on the number
of outcome events available for analysis, not the number of
subjects studied or the length of follow-up.
The next requirement for a novel risk marker is that it
improves risk prediction beyond established risk markers;
that is, new markers should provide incremental prognostic
information. For example, in the primary prevention of
coronary disease, it is recommended that established car-
diac risk factors be assessed in all at-risk individuals,
because they are easily measured by inexpensive and
readily available tests that form the basis of accepted risk
management strategies (eg, lipid and blood pressure treat-
ments). The goal in the evaluation of a new risk marker for
use in primary prevention is therefore to answer the
question, “Does the new marker add significant predictive
information beyond that provided by established cardiac
risk factors?” For example, a new marker that truly
indicated an individual’s biological age might be a better
marker of cardiovascular risk than the individual’s chro-
nological age. But this new marker would have to be
statistically associated with outcome after the effect of
chronological age has been accounted for in the risk
model, because measurement of chronological age is
simple, inexpensive, and readily available. In other words,
a novel marker of biological age must provide incremental
prognostic information to be of clinical value. When
statistical procedures are used to test for incremental
prognostic information, the new factor should be tested for
significance only after all established risk factors have
already been included in the model. In the example above,
the test of interest is whether biological age adds signifi-
cantly to a model that already includes chronological age,
not whether biological age is chosen before chronological
age in a stepwise variable-selection process.
More outcome events are needed to provide adequate
statistical power for the test of whether a new risk marker
adds prognostic information to established risk factors in a
multivariable model than for the test of whether the new
marker provides prognostic information by itself. Although
the exact number of events needed depends on the strength of
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each risk marker and the degree of correlation between them,
it would be difficult to test the value of the addition of a new
marker to an established marker with only a few outcome
events (eg, only 20 to 30) in the data set. If there are too few
events to provide adequate statistical power, it would be
unwarranted to declare that a new risk marker has no
independent predictive value.
Additional Practical Issues
The cost, safety, and acceptability of a novel risk marker
are additional important practical issues in the evaluation
of its value. A novel risk marker might occasionally offer
practical advantages over a standard risk marker, even if it
does not significantly improve risk prediction in a statis-
tical model. The novel marker may be simpler or safer to
measure, be more reproducible, or be less costly to assay
than a standard marker and thus may ultimately replace the
current standard risk marker. A technically simpler mea-
surement may offer significant practical advantages as a
risk marker; for example, an assay that requires less
stringent conditions in collection, storage, or handling of
the sample would be easier to apply clinically. Greater
precision and reproducibility of a laboratory result or less
observer variability in the interpretation of an imaging test
might make the novel risk marker simpler to use in clinical
practice. A marker with less variation within an individual
subject will also have greater precision. Finally, a test that
can be done at lower cost but with equivalent predictive
power would have an obvious advantage over a more
expensive standard.
The practical advantages of a novel risk marker may
argue strongly for its adoption, but a major question is
whether it will actually replace the current standard or
merely be used as an additional test. Very few new tests
completely replace older tests, so there is a strong likeli-
hood that the novel risk marker will simply be examined in
addition to the standard markers, in which case the criteria
for evaluation of incremental value should be applied.
Multimarker Risk Predictors
New genomic and proteomic techniques can measure
hundreds to thousands of markers in individual subjects. In
many studies, the number of markers available for analysis
greatly exceeds the number of subjects enrolled, which
raises several important methodological issues in the
evaluation of whether these markers are valid predictors of
clinical risk and whether they provide incremental predic-
tive value.
Whenever a large number of potential markers is tested,
some will be associated with the outcome by random chance
alone. The discovery of a predictor after many potential
predictors have been screened must therefore be replicated to
test properly the hypothesis that it is a significant predictor of
outcome. A simple approach is to perform a 10-fold cross-
validation of the novel marker within the initial sample of
subjects averaged over another 50-fold repetitions or by use
of the bootstrap method.5 Another approach is to test the
marker in an independent sample of subjects, such as a split
sample of the original cohort that was not used for discovery
of predictors. The strongest approach is to perform a rigorous
external validation study of the predictor in an entirely new,
independent cohort of subjects.
Data from several novel markers (eg, multiple genetic
polymorphisms or a number of biomarkers) may be com-
bined to form a multimarker risk score. In such cases, a
distinction should be made between the specific markers
that were included in the multimarker score and the
particular scoring algorithm that was applied to the marker
data to produce the final score used in risk prediction. A
proper evaluation of a multimarker score includes replica-
tion of the specific proposed scoring algorithm in an
independent validation sample; changing the scoring algo-
rithm after its initial derivation produces a new multima-
rker risk score, even when the new algorithm is based on
the same set of markers that were used in the original
score. The algorithm used to produce the multimarker risk
score should be published to allow other investigators to
evaluate it independently. If the scoring algorithm is
considered proprietary, regulators and journal editors will
need to ensure that the same scoring methods were used in
validation studies as in the initial development study.
Measures of Risk Prediction
A major goal of developing new risk markers in the era of
personalized and predictive medicine is to improve risk
prediction, but how should this improvement be measured?
Various metrics have been proposed and used, each of
which has both strengths and limitations.
The basic level of assessment of a new marker is that of
statistical association. The P value for the inclusion of the
novel marker in a multivariable statistical model is an
attractive measure, because statistical significance is a nec-
essary criterion in the evaluation of any new risk marker. The P
value, however, highly depends on the number of outcome
events analyzed; if there are too few events, even a strong risk
marker may be declared not significant, whereas if there are
large numbers of events, even a weak risk marker may be
declared statistically significant. Although a significant P value
is a necessary condition for a new marker, a significant proba-
bility value alone is not sufficient to establish the predictive
value of a novel marker.
The likelihood ratio partial 2 is another sensitive index
of information added by the inclusion of a new marker in
a prognostic model. This measure also depends, however,
on the number of events available for analysis, and it too
provides no direct assessment of predictive accuracy.
Another common measure of a risk marker is the
numerical value of the odds ratio, risk ratio, or hazard ratio
for its statistical association with outcome. For example, a
risk marker with an odds ratio of 4.5 would appear to be a
more powerful predictor than a risk marker with an odds
ratio of 1.5. The size of the odds ratio depends on the units
of measurement, however, so some form of standardization
is necessary before different risk markers can be compared
(eg, division of the units of measurement of a continuous
measure by the standard deviation or interquartile range of
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the marker levels in the population). Furthermore, even
after standardization, the population prevalence of the 2
risk markers must also be considered when one compares
their relative importance in risk prediction. A risk marker
with a high odds ratio but that is rare in the population may
be less useful in risk prediction than another marker with
a lower odds ratio that is common in the population. The
population-attributable risk of a marker increases directly
with both greater prevalence in the population and higher
odds ratios associated with a risk marker. Finally, even a
fairly strong risk marker may be less useful as a predictor,
because odds ratios or hazard ratios may be affected more
by the tails of the test distribution than by overall accuracy
or discrimination of the marker or risk tool.
The c-index, which is equivalent to the area under the
receiver operating characteristic curve for binary depen-
dent variables, has also been used as a measure of the
predictive value of novel risk markers.5–7 In this setting,
the c-index measures the probability that a randomly
chosen individual who experienced an event at a certain,
specific time has a higher risk score than a randomly
chosen individual who did not experience an event during
the same, specific follow-up interval. Thus, the c-index
measures how well a risk marker discriminates between
individuals at different risk levels. Although the c-index
assesses the rank order of risk predictions assigned to
individuals in a population, it does not test whether the risk
predictions are accurate or whether the risk model is well
calibrated. Moreover, the c-index is relatively insensitive to
change and may not increase appreciably even when a new
marker is statistically significant and independently associ-
ated with risk.8,9 Despite its limitations, the c-index is a
standard measure of the effect of a new marker in risk
prediction and helps to quantify its predictive discrimination.
The accuracy (or calibration) of risk prediction is also an
important measure of a risk marker, because it is the
absolute level of an individual’s risk that determines
whether the adverse effects and costs of therapy are
justified. Calibration means that a group of subjects with a
5% predicted risk will actually experience events at the 5%
rate; incorrect decisions might be made if the predicted
risk were too high or too low. The calibration of a risk
predictor can be measured by comparing the predicted
frequency of events with the observed frequency; for
instance, the population can be divided into groups with
different levels of predicted risk, and the predicted pro-
portion of events can be plotted against the observed
proportion of events (Figure 1). In a well-calibrated risk
model, all the data points would fall on the 45° line of
identity, whereas in an inaccurate or poorly calibrated
model, the points would deviate substantially from the line
of identity. Calibration of risk prediction can be assessed
by a goodness-of-fit test.10 Because the degree of calibra-
tion may depend on the choice of risk categories, use of a
smoothing function may be preferred, because it allows the
calibration of predictions to be assessed over the range of
values without imposing arbitrary divisions on the data.11
Calibration is an important property of a risk marker, but
it too provides an incomplete measure of marker perfor-
mance. It is also important that the marker discriminate
risk levels among individuals across a broad range of
predicted risk scores. A well-calibrated risk score that
classifies individuals into widely different risk groups is
clearly more useful than one that does not.
Because prediction using new risk tools and new mark-
ers involves more than association, discrimination, and
calibration, new statistical measures have been proposed
recently to assess the degree to which a novel risk marker
improves risk classification. Pencina and associates12,13
have proposed the integrated discrimination improvement
(IDI) test as a new measure of the predictive value of risk
markers. The IDI test measures the extent to which the use
of a new risk marker correctly revises upward the predicted
risk of individuals who experience an event and correctly
revises downward the predicted risk of individuals who do
not experience an event. The IDI test therefore gauges
whether a novel marker improves the level of discrimination
between groups of individuals classified with and without the
use of a new test. The IDI test appears to be more powerful
than the c-index for comparing 2 predictive systems.12
In summary, no single statistical measure assesses all
the pertinent characteristics of a novel risk marker. We
therefore recommend that several measures be reported in
papers evaluating novel risk markers, as summarized in
Table 1.
Clinical Value of Risk Markers and Risk
Prediction Methods
The various statistical measures discussed above are useful
in gauging the information provided by a new risk marker.
However, purely statistical measures do not assess the
clinical importance of the information provided by a new
risk marker, which might be assessed by its effect on
clinical decisions and ultimately on clinical outcomes.
The goal of measuring risk markers is not simply to
know an individual’s risk; rather, the goal is to use the risk
assessment to guide appropriate therapy and thereby im-
prove clinical outcomes. Some therapeutic measures can
be recommended regardless of an individual’s level of risk.
Figure 1. Predicted risk (horizontal axis) vs observed risk of
events (vertical axis), based on patients grouped into deciles of
predicted risk.
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For instance, a physician can advise any smoker to quit
smoking without measuring other cardiac risk markers.
The use of pharmacotherapy, however, must balance the
risks and costs of drug treatment with the expected benefits
within the context of the individual patient’s values. In the
prototypical decision about treatment (Figure 2A), there is
a risk threshold above which treatment is recommended
and below which it is not.14 Patients who have a risk that
is either just above or just below a treatment threshold
might be moved across the threshold and have their
treatment changed by the ascertainment of additional risk
information. If a test provides more risk information, there
is an intermediate risk zone (Figure 2B) in which the
results of testing should be used to guide treatment. For
very-low-risk patients, however, it is rational that neither
testing nor treatment is needed, whereas for high-risk
patients, treatment is indicated without further testing,
because no test result would reduce their estimated risk
below the treatment threshold.14
This prototypical treatment decision suggests that the
value of information provided by a test can be measured by
the likelihood that an individual’s predicted risk will be
modified sufficiently to cross a risk threshold and change
a treatment recommendation. The value of risk information
in this framework depends on the absolute accuracy of the
risk measurement, the effectiveness of the available treat-
ments in improving clinical outcomes, and the costs of
alternative treatment approaches. For example, in cardio-
vascular prevention, there are consensus risk thresholds
that indicate individuals in whom drug treatment should be
initiated or intensified.15 According to the recommenda-
tions of the Adult Treatment Panel III, a 2% annual risk of
a cardiac event is generally accepted as high enough to
initiate pharmacological therapy. By contrast, individuals
at 1% annual risk are generally not targeted for pharma-
cological intervention. Importantly, the exact levels of the
Adult Treatment Panel III thresholds for prevention may
be modified when the safety, efficacy, and cost profiles of
the various treatment options change. Nevertheless, be-
cause any treatment with benefits also has risks and costs,
there will always be risk thresholds for treatment.
After application of established risk markers, individu-
als will fall into risk zones with different treatment
recommendations (eg, the Adult Treatment Panel III cate-
gories: 1% per year, 1% to 2% per year, and 2% per
year). After measurement of a new risk marker, some of
the individuals will have their risk level changed suffi-
ciently to move from one risk/treatment category to
another. The net proportion of individuals who cross a
clinically relevant risk threshold as a result of using a
novel risk marker is then another measure of the value of
that risk marker. This basic approach can be generalized by
graphing the effect of the new risk marker on predicted
risk, with the initial prediction on the x-axis and the
revised prediction on the y-axis (Figure 3). The net
reclassification improvement test proposed by Pencina and
associates (or its generalization, the IDI) is a summary
measure of this concept.12
The concept of reclassification as a measure of a risk
marker is illustrated in Table 2 with data on high-density
lipoprotein as a risk predictor. The percentage of individ-
uals reclassified because of measurement of high-density
lipoprotein is one important measure of its value as a risk
marker. The effect of this reclassification cannot be
interpreted, however, without knowing whether the rate of
events in the individuals reclassified is more accurate. The
Figure 2. Clinical decisions vs predicted risk of disease (hori-
zontal axis). A, The decision to treat is based solely on the esti-
mated risk: Patients with risk levels below the treatment thresh-
old are not treated, whereas patients with risk levels above the
treatment threshold are given treatment. B, The possibility of
testing leads to 2 thresholds. Patients with risk levels below
threshold 1 are neither tested nor treated; patients with risk lev-
els between thresholds 1 and 2 are tested, and treatment rec-
ommendations are based on test results; patients with risk lev-
els above threshold 2 are treated without further testing.
Table 1. Recommendations for Reporting of Novel
Risk Markers
1. Report the basic study design and outcomes in accord with accepted
standards for observational studies4
2. Report levels of standard risk factors and the results of risk model
using these established factors
3. Evaluate the novel marker in the population, and report:
a. Relative risk, odds ratio, or hazard ratio conveyed by the novel
marker alone, with the associated confidence limits and P value
b. Relative risk, odds ratio, or hazard ratio for novel marker after
statistical adjustment for established risk factors, with the
associated confidence limits and P value
c. P value for addition of the novel marker to a model that contains
the standard risk markers
4. Report the discrimination of the new marker:
a. C-index and its confidence limits for model with established risk
markers
b. C-index and its confidence limits for model including novel marker
and established risk markers
c. Integrated discrimination index, discrimination slope, or binary R2
for the model with and without the novel risk marker
d. Graphic or tabular display of predicted risk in cases and noncases
separately, before and after inclusion of the new marker
5. Report the accuracy of the new marker:
a. Display observed vs expected event rates across the range of
predicted risk for models without and with the novel risk marker
b. Using generally recognized risk thresholds, report the number of
subjects reclassified and the event rates in the reclassified groups
2412 Circulation May 5, 2009
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sample data in Table 2 show that more case subjects had
risk reclassified upward than downward by the addition of
high-density lipoprotein to the risk model (29 versus 7),
but almost equal numbers of control subjects had their risk
reclassified upward and downward (173 versus 174, re-
spectively). Overall, the risk levels for individuals reclas-
sified because of high-density lipoprotein data in the risk
model were more accurate.
Cost-Effectiveness of Novel Risk Markers
Economic evaluation of laboratory tests is based on the principle
that the information provided by a test has value to the extent
that physicians use the information to change clinical
management and thereby improve clinical outcomes. In
this framework, the clinical effectiveness of a test is
gauged by its indirect effects on patient outcomes. Cost-
effectiveness analysis is a quantitative tool to weigh the
additional costs of a test or treatment against the additional
effectiveness of using the test to guide management.
Cost-effectiveness analysis first assesses the incremental
cost of using the novel risk marker rather than the standard
risk evaluation to guide management and then compares
the incremental cost to the incremental benefit of using the
new marker, which is assessed by changes in life expect-
ancy or quality of life.
The cost of performing the initial test is only part of the
total cost of a clinical management strategy that uses the
novel risk marker. The costs of follow-up tests are also a
part of an intention-to-test analysis, as are the costs of
subsequent therapy and outcomes. For example, the total
costs associated with the measurement of coronary calcium
include not only the cost of the initial computed tomogra-
phy scan but also the cost of follow-up testing (eg,
coronary angiography or evaluation of incidental pulmo-
nary findings), as well as therapies that were instituted on
the basis of the coronary calcium scores (eg, use of statins
or coronary revascularization). These downstream costs
induced by the test may be much greater than the cost of
the test itself, yet they must be included to provide a fair
picture of the economic consequences of the initial deci-
sion to obtain the test.
Although total costs may be increased by the use of a new
risk marker, testing may be a cost-effective strategy if clinical
outcomes are improved sufficiently. Effectiveness is mea-
sured in patient-centered terms in a cost-effectiveness analy-
sis, most typically as life-years added or quality-adjusted
life-years added, by a strategy of using the novel risk marker
compared with the alternative strategy of conventional risk
evaluation. Because the test has few, if any, direct effects on
these outcome measures, its clinical effectiveness depends on
how often it changes patient management and thereby
improves clinical outcomes. Only rarely has an outcomes-
based measure of the value of a new risk assessment test
been reported or evaluated for cardiovascular tests, how-
ever. Because of the high costs and potential harms of
some cardiovascular risk assessments (such as the risks of
radiation and contrast material from coronary angiography
with computed tomography), a careful assessment of cost-
effectiveness should be performed as part of a comprehensive
evaluation.
Phases of Evaluation of Risk Markers
Critical evaluation of novel risk markers should involve
several phases of increasing stringency, analogous to the
phases of development of a new drug. A new drug is
traditionally evaluated in small phase I studies to test
safety, then in medium-sized phase II studies to assess the
Figure 3. Individual patient pretest risk levels (horizontal axis)
and posttest risk levels (vertical axis) in relation to treatment
thresholds (light lines). Solid circles indicate patients who sub-
sequently developed an outcome event, and open circles indi-
cate patients who did not develop an outcome event. For larger
data sets, it may be preferable to display the data in 2 panels
rather than 1: The first panel for the patients who developed an
event (ie, the solid circles in Figure 3) and the second panel for
patients who did not (ie, the open circles in Figure 3). Tx indi-
cates treatment.
Table 2. Changes in Risk Levels by Use of an Additional
Risk Marker
Risk Levels in Model Without HDL
Risk Levels in Model With HDL
6% 6% to 20% 20%
Cases (n183)
6% 39 15 0
6%–20% 4 87 14
20% 0 3 21
Controls (n3081)
6% 1959 142 0
6%–20% 148 703 31
20% 1 25 72
Cases/total
6% 2.0% 9.6%   
6%–20% 2.6% 11.0% 31.1%
20% 0% 10.7% 22.6%
HDL indicates high-density lipoprotein.
A total of 383 subjects were reclassified as to risk level: 29 cases upward,
7 cases downward; 173 controls upward, 174 controls downward; net
reclassification index0.121, P0.001.
Data from Pencina et al.12
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effects of different doses, and is only approved for use
after large, comparative phase III studies that use random-
ized trials to establish its effect on clinical outcomes in
selected populations. Full adoption of a new drug often
depends on phase IV studies in larger numbers of patients
to further assess its clinical effectiveness and safety in
more general populations. An analogous phased-evaluation
strategy is appropriate for the adoption of novel risk
markers (Table 3).
The earliest phase of evaluation should establish
whether the novel risk marker can simply separate indi-
viduals according to risk of the outcome of interest.
Very-early-stage studies may be cross-sectional in design
and compare levels of the novel marker between individ-
uals with and without the outcome. This proof-of-principle
study solidifies the biological basis for the test as a risk
marker and can help identify critical values of the marker
to be tested in subsequent studies. Replication of initially
promising results in independent populations is clearly
desirable to justify larger prospective studies.
The second phase of evaluation of a novel risk marker is
validation in prospective studies that it predicts develop-
ment of hard outcomes, such as cardiac death, acute
myocardial infarction, or ischemic stroke. End points such
as chest pain or coronary revascularization are not optimal
to establish the value of a new risk marker, because they
are affected by subjective factors and may be artificially
increased if physicians or patients know of the results of
the risk marker study (eg, a positive imaging study might
lead to a coronary revascularization procedure). Some new
risk markers can be evaluated by use of a nested case-
cohort or nested case-control design, both of which allow
a prospective evaluation to be done very efficiently and
avoid the biases of a retrospective study design. Large
prospective, epidemiological cohort studies often store
samples of serum, plasma, or DNA for future analysis.
Marker levels measured in stored samples from cohort
members who developed cardiac events in follow-up can
be compared efficiently with levels in cohort members
who remained free of events. This approach is feasible for
biomarkers that are relatively unaffected by handling,
freezing, storage, and subsequent thawing, which is not the
case for all risk markers (eg, functional assays of protein
function or counts of circulating cells).
The third phase of evaluation of a novel risk marker is to
assess its incremental value in conveying predictive infor-
mation over and above that provided by established risk
markers (eg, the Framingham Risk Score in the setting of
primary prevention). A fair evaluation should be based on
a statistical test of whether the new marker adds significant
incremental prognostic information to a model that in-
cludes the established risk markers. The full prognostic
value of established markers should be incorporated in the
model (eg, analysis of age as a continuous variable provides
more information than analysis of age above or below 65 years)
to avoid artificially increasing the apparent value of the novel
risk markers. This phase of assessment should include a
report of discrimination, calibration, and reclassification as
discussed above.
The fourth phase of evaluation of a novel risk marker is
the assessment of its clinical utility. In a target population,
how often does use of the novel marker change individual
risk sufficiently to move patients across a critical risk
threshold and thereby change recommended therapy? The
net percentage of patients in the target population whose
therapy was changed provides a straightforward measure
of this criterion.
The final, definitive phase of evaluation is assessment of
whether the use of the risk marker in clinical management
improves clinical outcomes. The optimal test is a randomized
trial in which the outcomes of individuals whose management
is guided by the novel marker are compared with the
outcomes of patients who are managed in the conventional
fashion without the novel marker. Clinical outcomes, such as
cardiac events or symptoms, are the best measures of effec-
tiveness in such a trial. The cost-effectiveness of using the
novel marker as part of clinical management can also be
assessed on the basis of the net effect of a clinical strategy on
both clinical outcomes and costs. Randomized trials of
diagnostic tests or screening strategies have been conducted
in cardiovascular medicine,16–18 although not as frequently as
randomized trials of drugs and devices.
Conclusions
The increased availability of novel markers for cardiovas-
cular risk warrants a systematic approach to determine
their value for the clinical management of individual
patients. We have proposed a framework for the evaluation
of novel risk markers and have made a number of specific
recommendations for reporting the results of studies using
novel markers in risk assessment (Table 1). We believe
that an organized approach to the development and critical
appraisal of novel risk markers will contribute to the
improved clinical management of patients at risk of
cardiovascular disease.
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Table 3. Phases of Evaluation of a Novel Risk Marker
1. Proof of concept—Do novel marker levels differ between subjects with
and without outcome?
2. Prospective validation—Does the novel marker predict development of future
outcomes in a prospective cohort or nested case-cohort/case-cohort study?
3. Incremental value—Does the novel marker add predictive information to
established, standard risk markers?
4. Clinical utility—Does the novel risk marker change predicted risk
sufficiently to change recommended therapy?
5. Clinical outcomes—Does use of the novel risk marker improve clinical
outcomes, especially when tested in a randomized clinical trial?
6. Cost-effectiveness—Does use of the marker improve clinical outcomes
sufficiently to justify the additional costs of testing and treatment?
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In the scientific statement by Hlatky et al, “Criteria for Evaluation of Novel Markers of
Cardiovascular Risk: A Scientific Statement From the American Heart Association,” which
published ahead of print on April 13, 2009, and appeared in the May 5, 2009, issue (Circulation.
2009;119:2408–2416), several corrections were needed.
On page 2408, Yuling Hong, MD, PhD, FAHA, should be included as an author. On page 2415,
Dr Hong’s disclosure information has been added to Writing Group Disclosure table. At the time
of the development of the statement, Dr Hong was employed by the American Heart Association
and had no disclosures to report. Dr Hong’s current employment is the Centers for Disease Control
and Prevention in Atlanta, Ga.
These corrections have been made to the current online version of the article, which is available
at http://circ.ahajournals.org/cgi/content/full/119/17/2408.
The American Heart Association regrets this omission.
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